


PHARMACEUTICAL 2021



Eton Pharmaceuticals Inc. Rank 351 of 409





PHARMACEUTICAL 2021



Eton Pharmaceuticals Inc. Rank 351 of 409

The relative strengths and weaknesses of Eton Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eton Pharmaceuticals Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 49% points. The greatest weakness of Eton Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 296% points.

The company's Economic Capital Ratio, given in the ranking table, is -521%, being 166% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	24,701
Cost of Goods Sold	286
Intangible Assets	575
Liabilities, Current	3,794
Liabilities, Non-Current	99
Other Assets	232
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	6,763
Other Net Income	-859
Property and Equipment	811
Research and Development	14,104
Revenues	39
Selling, General and Administrative Expense	12,760

Output Variable	Value in 1000 USD
Assets	26,319
Liabilities	10,656
Expenses	27,150
Stockholders Equity	15,663
Net Income	-27,970
Comprehensive Net Income	-27,970
Economic Capital Ratio	-521%